Globally, approximately 20 million people are living with SCD, with the highest prevalence in regions such as sub-Saharan Africa, India, and the Mediterranean. In the United States alone, around 100,000 individuals are affected, with an estimated 1 in 365 African American births diagnosed with the disease. The prevalence of SCD is particularly concerning in regions with limited healthcare access, where many individuals remain undiagnosed and untreated, leading to higher morbidity and mortality rates.
The World Health Organization (WHO) estimates that SCD contributes to over 200,000 deaths annually, particularly in low-income countries. Increased awareness and improved screening programs are crucial in managing and reducing the disease's burden.
Market Forecast for Sickle Cell Disease
The global market for Sickle Cell Disease is poised for substantial growth in the coming decade. Factors contributing to this expansion include advancements in treatment options, a growing understanding of the disease, and ongoing research into novel therapies.
As of 2023, the SCD treatment market is valued at approximately USD 3 billion and is expected to grow at a compound annual growth rate (CAGR) of around 10% to reach approximately USD 6.5 billion by 2034. This growth is attributed to:
- Innovation in Treatment: The approval of new drugs, such as crizanlizumab (Adakveo) and voxelotor (Oxbryta), is diversifying treatment options and improving patient outcomes. Additionally, gene therapies are in clinical trials, promising long-term solutions for SCD.
- Increased Awareness and Screening: Enhanced awareness campaigns and newborn screening programs are leading to earlier diagnoses and better management, thereby increasing demand for treatment.
- Emerging Markets: Developing regions are witnessing improved healthcare infrastructure, which is critical for diagnosis and treatment. The rise in healthcare investments in these areas will likely lead to increased access to therapies.
- Research and Development: Pharmaceutical companies are focusing on research and development to introduce new therapies, which is expected to significantly impact market growth.
In summary, the epidemiology of Sickle Cell Disease underscores a pressing need for improved healthcare interventions, while the market forecast suggests a positive trajectory towards enhanced treatment options and increased market value by 2034. As stakeholders prioritize SCD awareness and treatment, the future holds promise for those affected by this debilitating condition.
Latest Reports Offered By DelveInsight:
CD47 Antigen Inhibitors Market
DelveInsight’s “CD47 Targeting Therapeutics Market – Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the CD47 inhibitors, historical and forecasted epidemiology, competitive landscape as well as the CD47 inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
DelveInsight’s comprehensive report titled “Bacterial Vaginosis Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of bacterial vaginosis. The report presents historical and projected epidemiological data covering Total Prevalent Cases and Diagnosed Prevalent Cases of Bacterial vaginosis further segmented by Age.
DelveInsight's "Bile Duct Cancer Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Bile Duct Cancer, historical and forecasted epidemiology as well as the Bile Duct Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom and Japan.
Egfr-induced Skin Disorders Market
DelveInsight’s "EGFR Inhibitors-Induced Skin Disorders Market Insight, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
DelveInsight's "Endometrial Cancer Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Endometrial Cancer, historical and forecasted epidemiology as well as the Endometrial Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom and Japan.
DelveInsight's "Fragile X Syndrome (FXS) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Fragile X Syndrome (FXS), historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
